Dabelotine

Drug Profile

Dabelotine

Alternative Names: Dabelotine mesilate; Dabelotine mesylate; S 12024; S 120242

Latest Information Update: 17 Sep 2002

Price : $50

At a glance

  • Originator Servier
  • Class Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Dementia

Most Recent Events

  • 30 Jul 1998 A clinical study has been added to the pharmacokinetics section
  • 04 Mar 1997 A study has been added to the therapeutic trials and adverse effects sections
  • 22 Jan 1997 Phase-II clinical trials for Dementia in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top